Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
Kok PS, Forde PM, Hughes B, Sun Z, Brown C, Ramalingam S, Cook A, Lesterhuis WJ, Yip S, O'Byrne K, Pavlakis N, Brahmer J, Anagnostou V, Ford K, Fitzpatrick K, Bricker A, Cummins MM, Stockler M, Nowak AK; Thoracic Oncology Group of Australasia (TOGA) and PrECOG, USA. Kok PS, et al. Among authors: ford k. BMJ Open. 2022 Jan 25;12(1):e057663. doi: 10.1136/bmjopen-2021-057663. BMJ Open. 2022. PMID: 35078853 Free PMC article.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
Hayne D, Grummet J, Espinoza D, McCombie SP, Chalasani V, Ford KS, Frydenberg M, Gilling P, Gordon B, Hawks C, Konstantatos A, Martin AJ, Nixon A, O'Brien C, Patel MI, Sengupta S, Shahbaz S, Subramaniam S, Williams S, Woo HH, Stockler MR, Davis ID, Buchan N; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Hayne D, et al. BJU Int. 2022 May;129(5):591-600. doi: 10.1111/bju.15552. Epub 2021 Jul 30. BJU Int. 2022. PMID: 34273231 Free PMC article. Clinical Trial.
Advancing alternative methods to reduce animal testing.
Nelson CP, Brown P, Fitzpatrick S, Ford KA, Howard PC, MacGill T, Margerrison EEC, O'Shaughnessy J, Patterson TA, Raghuwanshi R, Rouse R, Stromgren S, Sung KE, Valerio LG Jr, Ward JL, Bumpus NN. Nelson CP, et al. Among authors: ford ka. Science. 2024 Nov 15;386(6723):724-726. doi: 10.1126/science.adg6228. Epub 2024 Nov 14. Science. 2024. PMID: 39541448
Cloverleaf Esophageal Diverticula.
Bhatt A, Ford K 3rd, Podgaetz E, Konda VJ, Nguyen AD. Bhatt A, et al. Among authors: ford k 3rd. Am J Gastroenterol. 2024 Oct 25. doi: 10.14309/ajg.0000000000003159. Online ahead of print. Am J Gastroenterol. 2024. PMID: 39450867 No abstract available.
Anti-CD49d Ab treatment ameliorates age-associated inflammatory response and mitigates CD8+ T-cell cytotoxicity after traumatic brain injury.
Chen Z, Ford KP, Islam MBAR, Wan H, Han H, Ramakrishnan A, Brown RJ, Villanueva V, Wang Y, Davis BT 4th, Weiss C, Cui W, Gate D, Schwulst SJ. Chen Z, et al. Among authors: ford kp. J Neuroinflammation. 2024 Oct 19;21(1):267. doi: 10.1186/s12974-024-03257-7. J Neuroinflammation. 2024. PMID: 39427160 Free PMC article.
1,135 results